Last reviewed · How we verify
Olivia Cardenas-Trowers, M.D. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Bladder instillation WITHOUT triamcinolone acetonide | Bladder instillation WITHOUT triamcinolone acetonide | phase 3 | Urology | |||
| Bladder instillation WITH triamcinolone acetonide | Bladder instillation WITH triamcinolone acetonide | phase 3 | Corticosteroid (intravesical instillation) | Glucocorticoid receptor | Urology / Immunology |
Therapeutic area mix
- Urology · 1
- Urology / Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Olivia Cardenas-Trowers, M.D.:
- Olivia Cardenas-Trowers, M.D. pipeline updates — RSS
- Olivia Cardenas-Trowers, M.D. pipeline updates — Atom
- Olivia Cardenas-Trowers, M.D. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Olivia Cardenas-Trowers, M.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/olivia-cardenas-trowers-m-d. Accessed 2026-05-16.